Costo-efficacia di IMI/CIL/REL rispetto a CMS+IMI per il trattamento di infezioni batteriche Gram-negative non sensibili ai carbapenemi

OBJECTIVE: The objective of this analysis was to evaluate the cost-effectiveness of imipenem/cilastatin/relebactam compared to colistin-imipenem in the treatment of hospitalized patients with Gram-negative bacterial infections caused by imipenem-resistant pathogens. The perspective was both that of...

Descripción completa

Detalles Bibliográficos
Autores principales: Paoletti, Martina, Marcellusi, Andrea, Yang, Joe, Mennini, Francesco Saverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105322/
https://www.ncbi.nlm.nih.gov/pubmed/37070067
http://dx.doi.org/10.33393/grhta.2023.2488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10105322/
https://www.ncbi.nlm.nih.gov/pubmed/37070067
http://dx.doi.org/10.33393/grhta.2023.2488

Ejemplares similares